Pharsight

Drugs that contain Ibuprofen

1. Caldolor patents expiration

CALDOLOR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(5 years from now)

US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(6 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

US11806400 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Nov 19, 2024

Market Authorisation Date: 11 June, 2009

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Manage...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

2. Children's Advil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(2 months from now)

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

CHILDREN'S ADVIL family patents

Family Patents